First patient enrolled in Phase 2 FALCON trial of TERN-601 for obesity with 12-week data expected 4Q25 ...

SK Life Science, Inc., a U.S. pharmaceutical company developing treatments for central nervous system (CNS) disorders and a subsidiary of SK Biopharmaceuticals Co., Ltd., today announced the ...

You are free to share (copy and redistribute) this article in any medium or format and to adapt (remix, transform, and build upon) the material for any purpose, even commercially within the parameters ...

A bacterium makes a molecule that kills drug-resistant fungi in an unusual way — by targeting various phospholipid molecules ...

Majority of Participants Reached a Defined Threshold for Remission of Tardive Dyskinesia Regardless of Underlying Psychiatric Disorder <l ...

As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...

Sarepta will update Elevidys’ label after a patient died following treatment; the FDA issues flu vaccine recommendations ...

The development of smart moisture analyzers with integrated digital platforms is also revolutionizing the market. These ...

Cytokinetics is now rapidly moving into commercialization efforts with Aficamten. Read more to see why I rate CYTK stock a ...

After hours: March 18 at 7:37:44 PM EDT Loading Chart for NNVC ...

Through it all, a few overarching style motifs were likely present: Think flower crowns during festival season, indie sleaze ensembles complete with slouchy bags and practical boots, and—perhaps most ...

NDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGSIf approved, FILSPARI could become the first and ...